EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)
January 04, 2024 08:00 ET
|
EG 427
EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) In a non-clinical pharmacology study in an OAB model,...
EG 427 announces final Series A closing, achieving €18 million in total funds raised
July 13, 2023 02:00 ET
|
EG 427
Paris, France, 13 July, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today the final closing of a Series A financing. EG 427 raised an...
EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment
April 11, 2023 08:00 ET
|
EG 427
Issued European and Japanese patents cover herpes simplex virus (HSV) vectors selectively inhibiting subtype of sensory neuronsRelated initial therapeutic indications encompass multiple bladder...
EG 427 Appoints New Members To Board of Directors and Scientific Advisory Board
March 27, 2023 08:00 ET
|
EG 427
Venture and pharmaceutical industry veteran, Sundar Kodiyalam, becomes a new member on Board of Directors. Leading expert in herpes virus vector research, Gregory A. Smith, Ph.D., joins Scientific...
EG 427 appoints Cornelia Haag-Molkenteller, M.D., Ph.D., as Chief Medical Officer
November 29, 2022 05:00 ET
|
EG 427
PARIS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions based on its unique non-replicative HSV-1 vector platform,...
EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research
September 14, 2021 01:00 ET
|
EG 427
PARIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company leading the development of pinpoint gene therapy solutions by using a unique HSV-1 vector platform, today announced the...
EG 427 announces €12 million Series A financing to advance its HSV-1 based gene therapy
March 01, 2021 08:00 ET
|
EG 427
David Lamond and Stephane Boissel join the company’s board of Directors PARIS, March 01, 2021 (GLOBE NEWSWIRE) -- EG 427, a biotechnology company developing pinpoint gene therapy, today announced...